6 results about "Aseptic inflammation" patented technology

The invention discloses swelling and pain relieving ointment for pyretic arthralgia and a preparation method thereof. The swelling and pain relieving ointment is prepared from the following components: 30 to 50 parts of radix et rhizoma rhei, 30 to 50 parts of radix scutellariae, 30 to 50 parts of cortex phellodendri, 30 to 50 parts of radix angelicae, 30 to 50 parts of rhizoma arisaematis, 30 to 50 parts of radix trichosanthis, 10 to 20 parts of rhizoma atractylodis, 30 to 50 parts of rhizoma curcumae longae, 20 to 40 parts of myrrh, 10 to 20 parts of mirabilite, 10 to 20 parts of alum and 5 to 15 parts of borneol. The swelling and pain relieving ointment for pyretic arthralgia has remarkable effects of diminishing inflammation, relieving swelling and relieving pain. Clinical application verifies that the traditional Chinese medicine composition can quickly relieve aseptic inflammation and red, swollen and heat pain symptoms of joints and local soft tissues. The external use mode is convenient and practical, and patients can operate by themselves without complex procedures. Meanwhile, the plaster adopts a pure traditional Chinese medicine formula, is nontoxic and free of side effects, and avoids irritation of oral medicines to gastrointestinal tracts. According to the traditional Chinese medicine composition, cold medicines are used as main medicines, meanwhile, warm medicines such as rhizoma arisaematis and radix angelicae are combined, and cold and warm medicines are used together, so that the main effects of clearing heat and eliminating dampness are guaranteed, cold congealing and dampness obstructing caused by excessive cold and cool are prevented, and the ingenious idea of'counter-assistant 'of traditional Chinese medicine is embodied.

This utility model relates to medicine and can be used in neurosurgery. It is used as a means of accessing the intervertebral disc between the 5th lumbar and 1st sacral vertebrae at a 90-degree angle for laser vaporization. The utility model achieves the following technical results: 1. A minimally invasive, minimally invasive approach to the intervertebral disc at the L5-S1 level. 2. Allows to improve the effectiveness of treatment and achieve maximum pain relief in polysegmental lesions of intervertebral discs 3. Prior to this utility model, attempts were made to perform laser vaporization of the disc at the L5-S1 vertebral body level from anatomically inconvenient locations, which was accompanied by a long time interval, prolonged pain for the patient, the end of the electrode was not in the center of the nucleus pulposus, sometimes even on the cortical layer of the vertebral bodies, as a result of which the maximum effect of vaporization was not obtained, or aseptic inflammation of the bone tissue of the vertebrae was obtained. This utility model eliminates the above-mentioned issues, reducing vaporization time. The essence of this utility model is that, using this trocar and drilling stylet, we provide direct access to the L5-S1 intervertebral disc. Laser vaporization of this disc has not previously been performed due to its anatomical limitations.

Compositions for identifying a pathogenic bacterial infection include a mannitol compound with one or more substituents including radioisotopes. These radiopharmaceuticals, such as a positron-emitting mannitol analogue, [18F]fluoromannitol ([18F]FMtl), are rapidly taken up by gram-positive and gram-negative bacteria such as E. coli, S. aureus, A. baumannii, S. epidermis, P. mirabilis, S. enterica, K. pneumonia, E. faecium, E. cloacae, and M. marinum, but not non-active infection sites such as sterile inflammatory sites, cancer sites, etc. Administration of these radiopharmaceuticals to and subsequent imaging of patients, e.g., via positron emission tomography (PET), enables detection of deep-seated and difficult to manage bacterial infections, such as osteomyelitis and prosthetic joint infection, or in patients with sickle cell disease. [18F]FMtl injection detects and differentiates infection rapidly. The radiolabeled mannitol compounds can be produced via nucleophilic substitution reactions that are deployable on commercially available synthesizers, facilitating straightforward and wide accessibility, and counteracting unnecessary antibiotic use.

1. The name of the design product: rehabilitation therapy instrument. 2. The use of the design product: rehabilitation therapy for sports injury, postoperative rehabilitation and aseptic inflammation of human or small animals. 3. The design points of the design product: in shape. 4. The picture or photo that can best show the design points: perspective view.

The invention discloses a drug-loaded fibrous membrane as well as a preparation method and application thereof. The drug-loaded fibrous membrane comprises an active drug and a matrix membrane, the active medicine comprises pecedatinib or pharmaceutically acceptable salt thereof, and the matrix membrane has a fiber structure. The preparation method comprises the following steps: carrying out electrostatic spinning on a spinning solution containing an active drug, a matrix component and a solvent, thereby obtaining the product, wherein the active medicine comprises pecedatinib or a pharmaceutically acceptable salt of the pecedatinib. The drug-loaded fibrous membrane can maintain good physical and chemical properties of the fibrous membrane while loading drugs, can ensure slow release of drugs and significantly inhibit the occurrence of aseptic inflammation problems in practical application, and shows extremely high biocompatibility and safety.

The invention belongs to the technical field of medical materials, and discloses a preparation method of a stent for repairing alveolar bone defect, which comprises the following steps: S1, preparation of magnesium-doped hydroxyapatite: mixing a water-soluble calcium salt solution and a water-soluble magnesium salt solution into a water-soluble phosphate solution, stirring, and carrying out hydrothermal reaction to obtain a magnesium-doped hydroxyapatite material; the preparation method comprises the following steps: S1, carrying out fused deposition molding on a mixed material containing magnesium-doped hydroxyapatite and racemic polylactic acid to obtain a racemic polylactic acid-based degradable material; s3, based on the CBCT image of the alveolar bone defect patient, designing a personalized alveolar bone repair stent by using a reverse engineering technology, and arranging a retention form and a nail channel for accommodating an implant on the stent; and S4, manufacturing the alveolar bone repair scaffold based on a 3D printing process and the racemic polylactic acid-based degradable material. The stent can effectively solve the problem of aseptic inflammation caused by degradation of polylactic acid in vivo; good initial stability is provided for the implant in alveolar bone defects, and the implant has a wide medical application prospect.